Asia-Pacific Molecular Oncology Diagnostics Market: Focus on Cancer Type, End User, and Country - Analysis and Forecast, 2024-2033
The Asia-Pacific molecular oncology diagnostics market was valued at $513.6 million in 2024, and the market is expected to grow with a CAGR of 12.99% and reach $1,542.0 million by 2033.
Europe Molecular Oncology Diagnostics Market: Focus on Cancer Type, End User, and Country - Analysis and Forecast, 2024-2033
The Europe molecular oncology diagnostics market was valued at $606.0 million in 2024, and the market is expected to grow with a CAGR of 10.78% and reach $1,523.4 million by 2033
Asia-Pacific Proteomics Market: Focus on Offerings, Application, and Country - Analysis and Forecast, 2024-2034
The Asia-Pacific proteomics market is projected to reach $25.78 billion by 2034 from $6.95 billion in 2024, growing at a CAGR of 14.01% during the forecast period 2024-2034.
Europe Proteomics Market: Focus on Offerings, Application, and Country - Analysis and Forecast, 2024-2034
The Europe proteomics market is projected to reach $27.43 billion by 2034 from $8.77 billion in 2024, growing at a CAGR of 12.07% during the forecast period 2024-2034.
Need reports on an on-going basis? Do consider our
annual subscription
Europe Precision Medicine Market: Focus on Ecosystem and Country - Analysis and Forecast, 2024-2034
The Europe precision medicine market is projected to reach $118.79 billion by 2034 from $40.75 billion in 2024, at a CAGR of 11.29% during the forecast period of 2024-2034.
Nucleic Acid Therapeutics CDMO Market - A Global and Regional Analysis: Focus on Chemical Synthesis Method, Product, Disease Type, End User, and Region - Analysis and Forecast, 2025-2035
The global nucleic acid therapeutics CDMO market is rapidly expanding as demand for mRNA and gene therapies rises, driving CDMOs to scale production and support biotech and pharmaceutical companies
Asia-Pacific Precision Medicine Market: Focus on Ecosystem and Country - Analysis and Forecast, 2024-2034
The Asia-Pacific precision medicine market is projected to reach $158.92 billion by 2034 from $40.44 billion in 2024, at a CAGR of 14.67% during the forecast period of 2024-2034.
Clinical Biomarkers Market - A Global and Regional Analysis: Focus on Offering, Clinical Area, Technology, End User, and Region - Analysis and Forecast, 2025-2035
The global clinical biomarkers market is expected to grow at a CAGR of 10% during the forecast period from 2025 to 2035.
The global ultrasensitive molecular amplification market is witnessing significant growth, driven by advancements in diagnostic technologies, rising prevalence of infectious and genetic disorders, and increasing demand for early and precise detection methods.
The global oncology liquid biopsy market is experiencing significant growth, driven by the increasing prevalence of various cancers such as breast, prostate, lung, and colorectal cancer.
The U.S. Cervical cancer laboratory testing maket refers to diagnostic procedures used to detect abnormalities in the cervix that may lead to cervical cancer.
Genetic screening testing for preventive health market involves analyzing an individual’s genetic makeup to predict the likelihood of developing certain diseases or conditions in the future.
Genetic screening testing for reproductive health refers to a set of medical tests designed to assess the genetic makeup of individuals before or during pregnancy.
The north america immunoassay market is driven by advancements in healthcare, increasing disease prevalence, and a shift toward precision diagnostics.
The in-vitro diagnostics (IVD) market in North America is growing due to rising chronic diseases, technological advancements, and a shift toward personalized medicine.
Whole genome sequencing refers to the DNA sequencing of the entire genome, both coding and non-coding regions to detect inherited disease and track disease outbreaks.
Whole-exome sequencing is utilized to examine the protein-coding regions of the genome, aiming to reveal genetic factors that influence disease and population health.
Cardiac marker tests offer valuable information to healthcare providers, facilitating rapid diagnosis and risk stratification of cardiac events.
Incubator Systems Market explores market based on segmentations such as by technology, by end user, and by product type, the impact of macroeconomic factors market growth
The global clinical biomarkers market was valued at $24.80 billion in 2023 and is expected to reach $53.20 billion by 2033, growing at a CAGR of 7.93% between 2023 and 2033.
The global genomic cancer panel and profiling market is expected to reach $26.59 billion by 2033 from $9.90 billion in 2022.
In 2022, the India emerging infectious disease diagnostics market was valued at $339.1 million and is expected to grow at a CAGR of 10.29% during the forecast period 2023-2033 to register a value of $982.7 million in 2033.
The global gene fusion testing market was valued at $255.3 million in 2022 and is anticipated to reach $897.6 million by 2033, witnessing a CAGR of 12.25% during the forecast period 2023-2033.
The global rare disease genetic testing market was valued at $4.11 billion in 2022 and is anticipated to reach $16.69 billion by 2033, witnessing a CAGR of 13.69% during the forecast period 2023-2033.
The global MRD testing market is projected to reach $6.67 billion by 2033 from $1.47 billion in 2022, growing at a CAGR of 14.81% during the forecast period 2023-2033.
The global colorectal cancer screening and diagnostic market was valued at $15.28 billion in 2022 and is expected to reach $28.52 billion by 2033, growing at a CAGR of 5.93% during the forecast period 2023-2033.
In 2022, the global organ transplant diagnostics market was valued at $4.03 billion and is expected to reach $11.78 billion by 2033, with a CAGR of 10.45% during the forecast period 2023-2033.
The global nucleic acid therapeutics CDMO market was valued at $3.88 billion in 2022 and is expected to reach $14.19 billion by 2033, growing at a CAGR of 12.55% during the forecast period 2023-2033.
The Asia-Pacific and Middle East NGS market was valued at $1,055.6 million in 2022 and is anticipated to reach $2,370.7 million by 2027, witnessing a CAGR of 17.56% during the forecast period 2022-2027.
The global recombinant cell culture supplements market was valued $230.5 million in 2017 and is anticipated to reach $788.6 million by 2028.
The global molecular diagnostics market has been witnessing a steady growth since the end of the Human Genome Project in 2003. The market is expected to continue to grow with a double digit CAGR of 10.89% during the forecast period, 2018-2028.
The global precision medicine market is anticipated to reach $216.75 billion by 2028, witnessing a CAGR of 10.64% in the forecast period 2018-2028.
The global industrial microbiological QC market is expected to continue to grow with a single digit CAGR of 6.22% during the forecast period, 2019-2028.
The global direct-to-consumer market was valued at approximately $824.1 million in 2018 and is anticipated to reach $6,364.5 million by 2028.
The global pharmacogenomics market has been witnessing a steady growth since the end of the Human Genome Project in 2003. The market is expected to continue to grow with a double digit CAGR of 6.98% during the forecast period, 2019-2028.
The global single cell multi-omics industry analysis by BIS Research projects that the market was valued at $1.83 billion in 2018 and is anticipated to generate a value of $5.32 billion by 2025.
The global carrier screening market was valued at $846.9 million in 2018 and is estimated to grow over $2.93 billion by 2029.
The cell and gene therapy Industry analysis by BIS Research projects the market to grow at a significant CAGR of 36.52% during the forecast period, 2019-2025.
The NGS sample preparation industry analysis by BIS Research projects the market to grow at a significant CAGR of 15.54% during the forecast period, 2019-2025.
The hematologic malignancies testing industry analysis by BIS Research projects the market to grow at a significant CAGR of 15.24% during the forecast period, 2019-2025.
The global recombinant cell culture supplements market to grow at a significant CAGR of 12.93% during the forecast period, 2019-2029.
The global neoantigen cancer vaccine market to grow at a significant CAGR of 34.69% during the forecast period, 2023-2030.
The in-silico drug discovery industry analysis by BIS Research projects the market to grow at a significant CAGR of 12.92% during the forecast period, 2019-2029.
The nucleic acid isolation and purification industry analysis by BIS Research projects the market to grow at a significant CAGR of 5.98% during the forecast period, 2020-2029.
Global clinical biomarkers market analysis by BIS Research projects the market to grow at a significant CAGR of 10.07% during the forecast period, 2019-2029.
The global market for whole genome and exome sequencing is predicted to grow at a CAGR of 26.94% over the forecast period of 2019-2029.
The U.S. solid tumor testing market is projected to reach $15,396.4 million by 2030 from $8,179.7 million in 2019, at a CAGR of 5.91% during the forecast period 2020-2030.
The global companion diagnostics market to grow at a significant CAGR of 12.45% during the forecast period, 2020-2030.
The global market for hereditary genetic testing is predicted to grow at a CAGR of 13.59% over the forecast period of 2020-2030.
The market is predicted to grow at a CAGR of 13.12% over the forecast period of 2020-2030.
The global market for digital PCR (d-PCR) is predicted to grow at a CAGR of 17.57% over the forecast period of 2020-2025.
The global precision medicine market is expected to reach $278.61 billion by the end of 2030. The market is projected to grow at a CAGR of 11.13% during the forecast period, 2020-2030.
The global liquid biopsy market is projected to reach $12,933 million by 2030 from $2588.6 million in 2019, at a CAGR of 15.87% during the forecast period 2020-2030.
The spatial genomics and transcriptomics market to be one of the most rapidly evolving markets, which is predicted to grow at a CAGR of 23.20% during the forecast period of 2020-2030.
The global oncology precision medicine market was valued at $46.90 billion in 2019, and it is expected to grow at an impressive double-digit rate of 11.21% and reach a value of $148.66 billion in 2030.
The global market for MRD testing is predicted to grow at a CAGR of 15.64% over the forecast period of 2020-2025.
The global single-cell multi-omics market is projected to reach $3,188.9 million by 2025 from $1,221.5 million in 2020, at a CAGR of 21.16% during the forecast period, 2020-2025.
The global rare disease diagnostics market has been currently witnessing a rapid growth and is expected to continue to grow at a CAGR of 8.57% during the forecast period, 2020-2030.
The global market for flow cytometry in oncology is predicted to grow at a CAGR of 12.02% over the forecast period 2021-2031.
The global nucleic acid therapeutics CDMO market was valued at $1,546.4 million in FY2020 and is estimated to reach $4,463.7 million by 2030.
The global organ transplant diagnostics market is projected to reach $9,663.0 million by 2031, growing from $3,100.3 million in 2020, at a CAGR of 10.92% during the forecast period 2021-2031.
The global cell-free DNA isolation and extraction market was valued at $169.9 million in 2020 and is expected to reach $735.1 million by 2031, witnessing a CAGR of 14.19% during the forecast period 2021-2031.
The global liquid biopsy market is projected to reach $19,066.0 million by 2032 from $2,508.2 million in 2021 at a CAGR of 19.83% during the forecast period 2022-2032.
The minimal residual disease (MRD) testing market is projected to reach $2,611.2 million by 2027 from $1,089.3 million in 2021, at a CAGR of 14.53%.
The global hematologic malignancies testing market is projected to reach $11,680.1 million by 2032, growing from $2,606.5 million in 2021, at a CAGR of 14.23% during the forecast period 2022-2032.
In 2021, the global clinical biomarkers market was valued at $21,304.3 million, and it is expected to reach $54,294.0 million by 2032, growing at a CAGR of 8.73% during the forecast period 2022-2032.
The global digital PCR market is projected to reach $2,847.8 million by 2032 from $441.2 million in 2021, at a CAGR of 18.73% during the forecast period 2022-2032.
The global molecular oncology diagnostics market was valued at $3,620.6 million in 2021 and is anticipated to reach $12,130.5 million by 2032, witnessing a CAGR of 11.43% during the forecast period 2022-2032.
The U.S. prostate cancer testing market is anticipated to reach $1,901.6 million in 2030 from $544.1 million in 2021, with a CAGR of 14.7%, during the forecast period 2022-2030.
The global nucleic acid sample preparation market is projected to reach $11,200.5 million by 2032 from $4,213.0 million in 2022, growing at a CAGR of 10.27% during the forecast period 2022-2032.
The global targeted sequencing market is projected to reach $10,976.1 million by 2032 from $3,198.8 million in 2022, growing at a CAGR of 13.12% during the forecast period 2022-2032.
The Asia-Pacific and Middle East NGS market was valued at $1,055.6 million in 2022 and is anticipated to reach $2,370.7 million by 2027, witnessing a CAGR of 17.56% during the forecast period 2022-2027.
The global nucleic acid therapeutics CDMO market was valued at $3.88 billion in 2022 and is expected to reach $14.19 billion by 2033, growing at a CAGR of 12.55% during the forecast period 2023-2033.
In 2022, the global organ transplant diagnostics market was valued at $4.03 billion and is expected to reach $11.78 billion by 2033, with a CAGR of 10.45% during the forecast period 2023-2033.
The global colorectal cancer screening and diagnostic market was valued at $15.28 billion in 2022 and is expected to reach $28.52 billion by 2033, growing at a CAGR of 5.93% during the forecast period 2023-2033.
The global MRD testing market is projected to reach $6.67 billion by 2033 from $1.47 billion in 2022, growing at a CAGR of 14.81% during the forecast period 2023-2033.
The global gene fusion testing market was valued at $255.3 million in 2022 and is anticipated to reach $897.6 million by 2033, witnessing a CAGR of 12.25% during the forecast period 2023-2033.
The global rare disease genetic testing market was valued at $4.11 billion in 2022 and is anticipated to reach $16.69 billion by 2033, witnessing a CAGR of 13.69% during the forecast period 2023-2033.
In 2022, the India emerging infectious disease diagnostics market was valued at $339.1 million and is expected to grow at a CAGR of 10.29% during the forecast period 2023-2033 to register a value of $982.7 million in 2033.
The global genomic cancer panel and profiling market is expected to reach $26.59 billion by 2033 from $9.90 billion in 2022.
The global clinical biomarkers market was valued at $24.80 billion in 2023 and is expected to reach $53.20 billion by 2033, growing at a CAGR of 7.93% between 2023 and 2033.
I would like to extend our appreciation for your support in finalizing the report according to our precise needs and prerequisites. I am also impressed by the timely completion of all aspects of dealing with us as your esteemed client. I look forward to continue our professional relations in the future.
Manager-Strategy & Business DevelopmentICL Industrial Products
“I found the content quite interesting and insightful. It has provided us with some important information”
Strategic Insights COE ManagerJapan Tobacco International
I appreciate the extra effort that team BIS took to cater to our specific requirements, moreover, their response time and adaptability is at par with my expectation.
CEO & ChairmanTEKNA Plasma Systems
“BIS research has been a great support to our strategic investigation in the field of thermoplastic composite. BIS did manage to bring together a clear picture on a global level, supported by examples and references and they delivered an accurate evaluation of the current market size and potential in the coming years in line with our expectations. I warmly recommend them.”
VPFuture Business and Innovation